[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 170″]
Apple made headlines with a promise to spend repatriated dollars on R&D in the US. In this week’s podcast we talk with three Wall Street analysts to understand what we can expect to see from pharma and Medtech companies following the monster acquisitions of Juno, Kite et al. What ophthalmology companies might be acquisition targets? Will Medtech companies follow suit?